Skip to main content
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
How Care Works
Virtual & Home Visits
Virtual care across 40 states + house calls in Philadelphia
Concierge vs. Direct Care
Zero visit copays, zero hidden fees, relationship model
Send Medical Records
Securely upload prior labs & notes before consultation
Common Questions (FAQ)
PCP scope, insurance, labs & cancellation policies
Services
Primary Care & Acute Visits
Same-day sick visits, refills & comprehensive PCP care
Chronic & Complex Care
POTS, MCAS, Long COVID, Lyme & fatigue workups
Hormones & Endocrine
TRT, thyroid, perimenopause, menopause & PCOS
Metabolic Health & Weight
Advanced lipid testing, GLP-1s & glucose monitoring
Longevity & Prevention
Medicine 3.0 baselines, VO2 max, DEXA & prevention
All Clinical Services
Comprehensive catalogue of 36+ clinical services
Membership
Membership Details
Unlimited direct access, continuous physician care
Care Packages
The Reset & Strategic Roadmap evaluations
Billing & Payment FAQ
HSA/FSA eligibility, transparent cancellation policy
About
Meet Dr. Ash
Your Physician
GER·O·SPAN
Our Clinical Framework
Clinical Library & Articles
Evidence-based health guides reviewed by Dr. Ash
What People Say
124 patient reviews across 6 platforms
Contact Dr. Ash
Reach out with questions or book an intro
Patient PortalStart Intake
Low-Dose Statin Plus Ezetimibe Matches High-Dose Statin Protection With 41% Fewer Side-Effect Dropouts
Fishtown Medicine•8 min read

Low-Dose Statin Plus Ezetimibe Matches High-Dose Statin Protection With 41% Fewer Side-Effect Dropouts

Ashvin Vijayakumar MD

Medically Reviewed

Ashvin Vijayakumar MD•Updated November 7, 2026
On This Page
  • Does a family history of statin side effects mean I will react the same way?
  • Why does combining a low-dose statin with ezetimibe beat doubling the statin dose?
  • What are people afraid of with statins, and what do the trials show?
  • How do non-statin and combination options compare?
  • Where do combination therapy and bempedoic acid have limits?
  • How do we sequence your plan if you are statin-hesitant?
  • Common Questions
  • Does a family history of statin side effects mean I cannot take a statin?
  • Is a low-dose statin plus ezetimibe as effective as a high-dose statin?
  • What is the best non-statin pill if I cannot tolerate any statin at all?
  • Do statins cause dementia or permanent memory loss?
  • Deep Questions
  • Why does doubling a statin dose only add 6% more LDL lowering while ezetimibe adds 16% to 25%?
  • Does ezetimibe lower ApoB as much as it lowers LDL-C?
  • Why does bempedoic acid spare skeletal muscle while raising uric acid?
  • ✦Key Takeaways
  • Related at Fishtown Medicine
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR30-second take

Being nervous about statins is reasonable, and a family history of muscle aches does not mean you will react the same way. Most statin intolerance is dose-driven, tied to one specific molecule, or amplified by the nocebo effect. In the 3,780-patient RACING trial and an 8,180-patient pooled analysis, pairing a moderate statin (rosuvastatin 10 mg) with ezetimibe 10 mg matched high-dose statin monotherapy on 3-year cardiovascular events (7.5% vs 7.7%), put more people below an LDL-C of 70 mg/dL (73% vs 55%), and cut drug discontinuation or dose reduction by 41% (4.8% vs 8.2%). When even a tiny statin dose bothers your muscles, Fishtown Medicine uses liver-activated bempedoic acid (which cut heart attacks by 23% in the 13,970-patient CLEAR Outcomes trial), ezetimibe, or PCSK9 therapy to bring ApoB to target.

TL;DR: A parent who had a rough time on a statin is a reason to design a smarter plan so your plaque risk does not go untreated. Most statin muscle aches come from pushing a single drug dose too high. Each time you double a statin dose, you gain only about 6 percentage points of extra LDL cholesterol lowering while muscle side effects climb. Pairing a low or moderate statin dose with ezetimibe blocks cholesterol in both the liver and the gut, matching the cholesterol drop of a max-dose statin with 41% fewer people quitting for side effects (RACING trial). If your muscles cannot tolerate any statin at all, liver-specific bempedoic acid (CLEAR Outcomes) and injectable PCSK9 therapies lower ApoB without touching skeletal muscle.

Someone sits down with their lab report, looks at their family history, and names a clear fear: both parents felt awful on a statin, and they want another way. Sometimes the worry is muscle pain that ruined a parent's daily walks. Sometimes it is a deeper worry about harming memory, blood sugar, or cellular energy.

That hesitation deserves a serious clinical answer. The trap hiding inside "I cannot take a statin" is the belief that a high-dose statin is the only way to protect your arteries, and that one relative's bad reaction seals your fate. Neither premise holds up. Leaving a high ApoB particle count untreated for a decade carries a steep price, while modern lipid medicine gives us four distinct pathways to clear those particles comfortably.

Does a family history of statin side effects mean I will react the same way?

No, a parent's muscle aches rarely mean you cannot take a lipid-lowering medication, though that history changes how we start. Most people who react badly to a statin reacted to a high starting dose of a fat-soluble statin.

In the blinded SAMSON N-of-1 trial, patients with prior statin complaints rotated through months of statin, placebo, and empty bottles.1 Roughly 90% of the symptom burden people felt on the statin months also showed up on the placebo months.1 Those aches were physical sensations, but the pill was rarely the trigger. Expecting pain after watching a parent struggle sets up a powerful nocebo response.

A true genetic sensitivity does exist in a smaller group. A variant in the liver transporter gene SLCO1B1 slows how fast the liver clears certain statins, leaving more drug circulating near muscle fibers. Pharmacogenomic testing can check SLCO1B1 before you swallow a single tablet. Even when that variant is present, it mostly flags high-dose simvastatin or atorvastatin, pointing us toward a water-soluble option at a tiny dose or a non-statin pathway.

Why does combining a low-dose statin with ezetimibe beat doubling the statin dose?

Adding ezetimibe 10 mg to a low or moderate statin lowers LDL cholesterol (LDL-C) by an extra 16 percentage points of your starting baseline, matching the drop of three statin dose doublings without the muscle toll.24

Statin pharmacology follows the rule of 6. The first 10 mg tablet of atorvastatin does the heavy lifting, dropping LDL-C by about 37% and ApoB by 28%.6 Every time you double that dose - from 10 mg to 20 mg, 20 mg to 40 mg, and 40 mg to 80 mg - you gain only about 6 percentage points of extra LDL-C lowering per step, while muscle and blood-sugar side effects rise.67 Moving all the way from 10 mg to 80 mg is an 8-fold higher drug dose for just 17 extra percentage points of LDL-C reduction (-37% to -54%).6

Combination lipid therapy vs high-dose statin monotherapy across RACING, LODESTAR, and CLEAR Outcomes Figure: Dual-pathway therapy (blocking hepatic HMGCR synthesis and gut NPC1L1 absorption) vs. high-dose statin monotherapy and liver-specific bempedoic acid. In the pooled RACING and LODESTAR analysis (n = 8,180), combination therapy matched high-intensity statins on 3-year cardiovascular events (7.5% vs 7.7%, HR 0.98) while cutting intolerance discontinuation by 41%.

Your body fights single-pathway blockade. When a statin slows cholesterol production in the liver, your small intestine compensates by absorbing more cholesterol from food and bile.8 Ezetimibe blocks the intestinal NPC1L1 transporter that pulls that cholesterol in.8 Pairing atorvastatin 10 mg with ezetimibe 10 mg lowers LDL-C by 53% and ApoB by 43% - virtually identical to the -54% LDL-C and -46% ApoB of atorvastatin 80 mg, using one-eighth the statin dose.6

The RACING randomized trial (n = 3,780 patients with cardiovascular disease) tested rosuvastatin 10 mg plus ezetimibe 10 mg head-to-head against high-intensity rosuvastatin 20 mg for 3 years:2

  • Identical heart and stroke protection: The 3-year primary cardiovascular event rate was 9.1% on the combination vs 9.9% on high-dose rosuvastatin (meaning equal protection).2 In the 2025 JAMA Cardiology pooled patient-level analysis of RACING and LODESTAR (n = 8,180), the 3-year event curves lay right on top of each other (7.5% vs 7.7%, HR 0.98).3
  • More patients hit strict targets: At 1 year, 73% of combination patients reached LDL-C < 70 mg/dL vs 55% on high-dose monotherapy (18 percentage points higher), and 42% vs 25% reached < 55 mg/dL.2
  • 41% fewer patients had to stop or cut their dose: Intolerance led to stopping or dose reduction in 4.8% of combination patients vs 8.2% on high-intensity statin (p < 0.0001).2
  • Lower diabetes medication starts: In the 8,180-patient pooled analysis, new-onset diabetes was 10.2% vs 11.9% (p = 0.047), and starting a new diabetes drug fell from 8.2% to 6.5% (p = 0.020).3

What are people afraid of with statins, and what do the trials show?

Brain fog and mitochondrial energy loss are the two worries patients bring up most, and large randomized trials show no rise in dementia on statins while muscle CoQ10 shifts stay localized and manageable.911

The memory fear traces back to an old FDA label note based on scattered, reversible case reports. When researchers tested cognition formally in massive randomized trials - including PROSPER, the CTT meta-analyses, and the EBBINGHAUS cognitive sub-study that drove LDL-C down into the 20s and 30s - cognitive scores did not drop.911 Keeping small brain arteries free of plaque protects memory over decades, and the 2024 Lancet Commission on Dementia now lists high midlife LDL-C as a major modifiable dementia risk factor.

The mitochondrial question has documented biochemistry behind it. The hepatic pathway that builds cholesterol (HMG-CoA reductase) also makes ubiquinone (CoQ10), a carrier molecule inside the mitochondrial electron transport chain. High-dose fat-soluble statins can lower muscle CoQ10 levels and trigger aches in susceptible people. Two practical steps solve this: keep the statin dose low by pairing with ezetimibe, and add 100 to 200 mg of ubiquinol (CoQ10) if mild muscle tightness appears. Commercial blood tests sold to measure mitochondrial function directly rarely change that decision.

How do non-statin and combination options compare?

Lowering ApoB reduces cardiovascular events by roughly 22% to 25% per 39 mg/dL (1 mmol/L) drop in LDL-C, whether you get there with a statin, ezetimibe, bempedoic acid, or a PCSK9 inhibitor.12

Regimen / StrategyTypical LDL-C & ApoB DropOutcome Trial EvidenceMuscle & Metabolic Profile
High-Intensity Statin Alone (Rosuvastatin 20-40 mg or Atorvastatin 40-80 mg)-50% to -55% LDL-C** / **-45% ApoBClass I standard across decades of trials (CTT)Higher rate of dose-related muscle aches (8.2% intolerance in RACING) and small rise in blood sugar
Low/Moderate Statin + Ezetimibe (Rosuvastatin 5-10 mg or Atorvastatin 10 mg + Ezetimibe 10 mg)-50% to -53% LDL-C** / **-43% ApoBMatched high-intensity statin in RACING (n = 3,780) & LODESTAR (n = 8,180, HR 0.98)41% lower intolerance discontinuation (4.8% vs 8.2%); fewer new diabetes drugs (6.5% vs 8.2%)
Bempedoic Acid +/- Ezetimibe (Nexletol 180 mg or Nexlizet 180/10 mg)-21% alone** / **-38% with ezetimibeCLEAR Outcomes (n = 13,970 statin-intolerant): -13% MACE (HR 0.87), -23% heart attacks (HR 0.77)Liver-only activation (ACSVL1 absent in muscle); no excess myalgia (5.6% vs 6.8% placebo) or diabetes; watch uric acid (+0.8 mg/dL)
PCSK9 Inhibitors / Inclisiran (Repatha, Praluent, Leqvio)-50% to -60% LDL-C / -50% ApoB (+ -20-25% Lp(a))FOURIER & ODYSSEY OUTCOMES: -15% MACE down to LDL-C < 30 mg/dLZero muscle pathway overlap; subcutaneous injection every 2 weeks or twice a year

Where do combination therapy and bempedoic acid have limits?

Every lipid strategy carries trade-offs that deserve plain daylight before you pick a regimen:

  1. RACING's open-label design and population: All 3,780 patients in RACING (and all 4,400 in LODESTAR) were enrolled in South Korea under an open-label design.23 Knowing whether you are taking one high-dose pill or a low-dose combination can nudge how often patients report side effects. Also, combination therapy proved non-inferior (equal), not superior, for preventing heart attacks and strokes.23
  2. The ApoB gap with ezetimibe: Ezetimibe trims ApoB slightly less than it trims LDL-C. In FDA label data, adding ezetimibe to a statin cut LDL-C by 25% but ApoB by 19%.6 Atorvastatin 10 mg plus ezetimibe 10 mg lowers LDL-C by 53% (matching atorvastatin 80 mg at 54%), while ApoB drops 43% vs 46% on atorvastatin 80 mg.6 That is why we always recheck ApoB directly at 6 to 8 weeks.
  3. Bempedoic acid's kidney and tendon watchpoints: Bempedoic acid is a prodrug switched on by the enzyme ACSVL1, which lives in the liver and is absent in skeletal muscle.5 That explains why muscle aches in CLEAR Outcomes were slightly lower on bempedoic acid than on placebo (5.6% vs 6.8%).5 However, bempedoic acid mildly blocks the kidney transporter OAT2, which raises blood uric acid by an average of 0.8 mg/dL (10.9% vs 5.6% hyperuricemia; gout 3.1% vs 2.1%), nudges gallstones up (2.2% vs 1.2%), and carries a label warning to avoid use if you have a history of tendon rupture (1.2% vs 0.9%).5

How do we sequence your plan if you are statin-hesitant?

At Fishtown Medicine, we use If -> Then clinical decision rules anchored to your baseline ApoB, Lp(a), and tolerance history:

  • If you have never tried a statin but a parent had muscle aches -> Then we check TSH, 25-OH Vitamin D, baseline CK, uric acid, and optional SLCO1B1 pharmacogenomics, then start a hydrophilic micro-dose (rosuvastatin 2.5 mg or 5 mg, daily or three times weekly) paired early with ezetimibe 10 mg instead of pushing a high statin dose.
  • If you developed true muscle aches on 1 or 2 prior statins -> Then we pause until symptoms clear, re-trial once- or twice-weekly rosuvastatin 2.5 mg with ezetimibe 10 mg and CoQ10 100-200 mg, or step straight to bempedoic acid 180 mg + ezetimibe 10 mg (Nexlizet) if your baseline uric acid is < 6.0 mg/dL and you have no gout or tendon rupture history.
  • If your ApoB remains above target (< 70 mg/dL for prevention, < 50 mg/dL with plaque or high Lp(a)) -> Then we add or switch to a PCSK9 inhibitor or inclisiran and recheck ApoB in 6 to 8 weeks.

Note that a coronary calcium score of zero (CAC = 0) in an adult under 55 with high ApoB or high Lp(a) only rules out old, calcified plaque. When soft non-calcified plaque is the question, a coronary CT angiogram (CCTA) sees the arterial wall directly.

If you are in the Greater Philadelphia area and want a lipid plan built around your particle count and tolerance history, tell Dr. Ash what is going on at Fishtown Medicine.

✦

Key Takeaways

  1. The rule of 6 makes max-dose statin monotherapy an inefficient trade: Doubling a statin dose three times (10 mg -> 80 mg) multiplies drug exposure 8-fold for only about 17 extra percentage points of LDL-C lowering.
  2. Low/moderate statin plus ezetimibe matches high-intensity statin outcomes with better tolerance: In RACING (n = 3,780) and the RACING + LODESTAR pooled analysis (n = 8,180), combination therapy delivered identical 3-year cardiovascular protection (HR 0.98), put 73% vs 55% of patients below LDL-C 70 mg/dL, and cut intolerance discontinuation by 41% (4.8% vs 8.2%).
  3. Recheck ApoB on combination therapy: Because ezetimibe lowers ApoB slightly less than LDL-C (-19% vs -25% add-on), always verify the on-treatment ApoB particle count at 6 to 8 weeks.
  4. Bempedoic acid bypasses skeletal muscle: Activated by hepatic ACSVL1 (absent in muscle), bempedoic acid cut heart attacks by 23% (HR 0.77) and coronary revascularizations by 19% (HR 0.81) in CLEAR Outcomes (n = 13,970), requiring a baseline uric acid and tendon check before starting.
  5. A calcium score of zero (CAC = 0) does not rule out soft plaque under age 55: When ApoB or Lp(a) is high, treat the particle count or evaluate soft plaque directly with CCTA.

Related at Fishtown Medicine

  • Ezetimibe (Zetia): The Simple LDL-Lowering Add-On - how blocking gut NPC1L1 absorption pairs with low-dose statins
  • Bempedoic Acid (Nexletol): When Statins Are Not an Option - full CLEAR Outcomes data and uric acid / tendon rules
  • Beyond Statins: Lowering Cholesterol - the complete non-statin toolkit for lowering ApoB
  • ApoB and Heart Health - why particle count drives plaque more accurately than LDL-C
  • PCSK9 Inhibitors (Repatha, Praluent) - injectable therapy that drops ApoB by 50% to 60%
  • Stopping Statins and Heart Attack Risk - what the discontinuation data show and how to switch safely

Scientific References

  1. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects (SAMSON). New England Journal of Medicine. 2020;383(22):2182-2184.
  2. Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. The Lancet. 2022;400(10349):380-390.
  3. Lee YJ, Hong BK, Yun KH, et al. Alternative LDL Cholesterol-Lowering Strategy vs High-Intensity Statins in Atherosclerotic Cardiovascular Disease: A Systematic Review and Individual Patient Data Meta-Analysis. JAMA Cardiology. 2025;10(2):137-146.
  4. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). New England Journal of Medicine. 2015;372(25):2387-2397.
  5. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). New England Journal of Medicine. 2023;388(15):1353-1364.
  6. U.S. Food and Drug Administration. Zetia (ezetimibe) Prescribing Information - Clinical Studies Table (Atorvastatin + Ezetimibe LDL-C and ApoB Reductions). Updated 2025.
  7. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet. 2016;388(10059):2532-2561.
  8. Preiss D, Tobert JA, Hovingh GK, Reith C. Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar. Journal of the American College of Cardiology. 2020;75(16):1945-1955.
  9. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393(10170):407-415.
  10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). New England Journal of Medicine. 2017;376(18):1713-1722.
  11. Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab (EBBINGHAUS). New England Journal of Medicine. 2017;377(7):633-643.
  12. Silverman MG, Ference BA, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316(12):1289-1297.
Medical Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The patterns described are drawn from recurring clinical presentations, not any single patient. In the world of Precision Medicine, there is no "one size fits all" - the right medication, dose, and alternative must be matched to your unique labs, symptoms, and family history. Talk with Dr. Ash before starting, stopping, or changing any cardiovascular medication.
Ashvin Vijayakumar MD (Dr. Ash)

Fishtown Medicine | Cardiovascular risk

2418 E York St, Philadelphia, PA 19125·(267) 360-7927·hello@fishtownmedicine.com·HSA/FSA Eligible

Frequently Asked Questions

Common Questions

No, a family history of statin muscle aches does not mean you will react the same way. In blinded crossover trials like SAMSON, roughly 90% of muscle symptoms reported on a statin also occurred on placebo, and most true pharmacologic intolerance comes from high doses of fat-soluble statins. Fishtown Medicine starts statin-hesitant patients on low-dose water-soluble regimens paired with ezetimibe or uses SLCO1B1 genetic testing to pick a well-tolerated pathway.
Yes. In the 3,780-patient RACING trial and an 8,180-patient pooled analysis with LODESTAR, rosuvastatin 10 mg plus ezetimibe 10 mg matched high-intensity rosuvastatin 20 mg for preventing cardiovascular death, heart attack, and stroke over 3 years (7.5% vs 7.7%, HR 0.98). The combination got more patients below an LDL-C of 70 mg/dL (73% vs 55%) and cut drug discontinuation or dose reduction for side effects by 41% (4.8% vs 8.2%).
For patients who cannot tolerate even a low-dose statin, bempedoic acid (Nexletol 180 mg) paired with ezetimibe (Zetia 10 mg, combined as Nexlizet) lowers LDL-C by about 38% without activating in skeletal muscle. In the 13,970-patient CLEAR Outcomes trial, bempedoic acid reduced major cardiovascular events by 13% (HR 0.87) and heart attacks by 23% (HR 0.77) with no increase in muscle aches (5.6% vs 6.8% on placebo).
No. Large randomized controlled trials and pooled meta-analyses, including PROSPER, the Cholesterol Treatment Trialists' Collaboration, and the EBBINGHAUS cognitive trial, show no increase in dementia or lasting cognitive decline on statin or PCSK9 therapy. Lowering ApoB in midlife protects the small blood vessels of the brain and reduces long-term vascular dementia risk.

Deep-Dive Questions

Statins inhibit hepatic HMG-CoA reductase on a log-linear curve, where the first 10 mg dose captures most of the enzyme blockade and each subsequent doubling adds only about 6 percentage points of baseline LDL-C reduction. At the same time, blocking liver synthesis triggers a compensatory spike in intestinal cholesterol absorption through the NPC1L1 brush-border transporter. Adding ezetimibe 10 mg shuts down that compensatory gut absorption, lowering on-statin LDL-C by an extra 23% to 25% (about 16 percentage points of original baseline), equal to nearly three statin doublings.
Ezetimibe lowers ApoB slightly less than it lowers LDL-C. In FDA label data, adding ezetimibe 10 mg to an ongoing statin lowers LDL-C by 25% and ApoB by 19%. Comparing regimens directly, atorvastatin 10 mg plus ezetimibe 10 mg lowers LDL-C by 53% and ApoB by 43%, whereas high-dose atorvastatin 80 mg lowers LDL-C by 54% and ApoB by 46%. Because plaque risk tracks ApoB particle count, Fishtown Medicine measures ApoB directly 6 to 8 weeks after starting combination therapy to confirm the particle goal is met.
Bempedoic acid is an inactive prodrug that requires the enzyme very-long-chain acyl-CoA synthetase 1 (ACSVL1, encoded by SLC27A2) to convert into active bempedoyl-CoA. ACSVL1 is expressed in hepatocytes and kidney cells but is absent in human skeletal muscle, so muscle fibers never experience pathway blockade. In the kidney, bempedoic acid weakly inhibits organic anion transporter 2 (OAT2), which slows tubular secretion of uric acid and creatinine, raising serum uric acid by an average of 0.8 mg/dL (3.1% gout rate vs 2.1% on placebo in CLEAR Outcomes).

Ready when you are

Start your intake

The chat is our AI assistant, answering from our published guides. To talk it through with Dr. Ash himself, start with the intake.

Related Intelligence

Your Relationship With Yourself: The Ground of Every Health Change | Fishtown Medicine

Your Relationship With Yourself: The Ground of Every Health Change | Fishtown Medicine

The relationships that shape your health reach beyond other people. The first one is with yourself: the story you tell, whether you choose yourself, and how you talk to yourself when it is hard. Why that relationship decides whether a health change sticks, from Fishtown Medicine in Philadelphia.

Read Deep Dive
Performance Physical Philadelphia: 4 Tests That Predict How You Age

Performance Physical Philadelphia: 4 Tests That Predict How You Age

A performance physical measures how well you are aging: VO2 max, grip strength, mobility, and body composition - the 4 tests that predict healthspan.

Read Deep Dive
Social Health Is Healthspan: What 80+ Years of Research Says About Relationships and Longevity

Social Health Is Healthspan: What 80+ Years of Research Says About Relationships and Longevity

More than 80 years of research connects relationships and community to how long and how well you live. A Philadelphia doctor on what to do about it day to day.

Read Deep Dive

New patients

Talk it through with Dr. Ash.

Share your numbers if you know them, your family history, and what you want to get ahead of. Dr. Ash reads every intake personally.

HSA/FSA eligible
No initiation or cancellation fees
No copays
Tell Dr. Ash what’s going on →
FishtownFish wrapped around the rod of AsclepiusMedicine
Preventive Primary Care
2418 E York St, Philadelphia, PA 19125(267) 360-7927Primary care in PhiladelphiaHome visits in Greater PhiladelphiaPricing & MembershipGER·O·SPAN: our clinical frameworkDigital Health LiteracyClinical Evidence & Research

Serving Fishtown · Northern Liberties · East Kensington · Olde Richmond · Port Richmond · Old City · Callowhill · Poplar · Center City · Center City West · Art Museum · Bella Vista · Chestnut Hill · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark · Bryn Mawr, PA · Gladwyne, PA · Villanova, PA · Wayne, PA · Cherry Hill, NJ · Haddonfield, NJ · Medford, NJ · Moorestown, NJ · Voorhees, NJ

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • Testosterone (TRT)
  • Sleep Apnea & Low T
  • Andropause
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack
  • Supplement Guides
Care in Philadelphia +
Direct Primary Care in Philadelphia, PAConcierge Medicine in Philadelphia, PAConcierge vs DPC in Philadelphia, PALongevity Medicine in Philadelphia, PAPreventive Care in Philadelphia, PAExecutive Physical in Philadelphia, PAAnnual Physical in Philadelphia, PAHealthspan Optimization in Philadelphia, PAFunctional Medicine in Philadelphia, PASame-Day Sick Visits in Philadelphia, PATestosterone Replacement Therapy in Philadelphia, PAPerimenopause Care in Philadelphia, PAMenopause Care in Philadelphia, PAThyroid Treatment in Philadelphia, PAPCOS Care in Philadelphia, PAGLP-1 Weight Loss in Philadelphia, PAMetabolic Health in Philadelphia, PAHormone Optimization in Philadelphia, PAAdvanced Lipid Testing in Philadelphia, PAVO2 Max Testing in Philadelphia, PADEXA Scan in Philadelphia, PACGM in Philadelphia, PALong COVID Care in Philadelphia, PAChronic Fatigue Treatment in Philadelphia, PAPOTS Treatment in Philadelphia, PAMCAS Treatment in Philadelphia, PALyme Disease Care in Philadelphia, PABrain Fog Treatment in Philadelphia, PASleep Disorders Treatment in Philadelphia, PAStrep Throat Treatment in Philadelphia, PAUTI Treatment in Philadelphia, PASinus Infection Treatment in Philadelphia, PASTI Testing in Philadelphia, PATravel Medicine in Philadelphia, PAPre-Op Clearance in Philadelphia, PASports Club Medicine in Philadelphia, PA

Made it this far? You’re already most of the way there. let’s get started → Dr. Ash reads every word personally.

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical IndependenceCare NetworkResearch & Monographs